CTIS2024-513581-19-00进行中（未招募）1 期
Inhibition of Mast cell Activation in AtheroScleroTic lesions using an Anti-IgE antibody approach (MAST) - 19-659
niversitair Medisch Centrum Utrecht0 个研究点目标入组 40 人开始时间: 2024年7月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Patient is 18 years or age or older., Patient is able and willing to give their consent and sign an informed consent., Patient has a symptomatic or asymptomatic atherosclerotic carotid artery stenosis of at least 50% narrowing of the lumen (calculated by using criteria equivalent to the NASCET method) wherefore revascularisation through carotid endarterectomy is plannend routinely.
排除标准
- •Previous anaphylactic reaction (e.g. food allergy, medication such as antibiotics), Previous carotid endarterectomy (CEA) or carotid artery stenting (CAS) in the ipsilateral artery., Patients with severe asthma or chronic urticaria which are treated or have been treated with omalizumab subcutaneously.
研究者
相似试验
进行中（未招募）
1 期
Medication for inhibition of activation of a certain immune cell in atherosclerotic lesionsAtherosclerosisEUCTR2019-002452-16-NLMC Utrecht80
尚未招募
2 期
Inhibition of Mast cell Activation in AtheroScleroTic lesions using an Anti-IgE antibody approach (MAST-trial)carotid narrowingatherosclerotic carotid artery stenosis10003216NL-OMON54785niversitair Medisch Centrum Utrecht80
招募中
不适用
Inhibition of Mast cell Activation in AtheroScleroTic lesions using an Anti-IgE antibody approach (MAST)Atherosclerotic narrowing of the carotid arteryNL-OMON23598ZonMW, Dutch Heart Foundation80
招募中
1 期
Clinical study for the treatment of atherosclerotic angiopathy with traditional Chinese MedicineatherosclerosisITMCTR1900002732Hebei Petro China Central Hospital
已完成
不适用
Prevention of atherosclerosis by SGLT2 inhibitor; multicenter, randomized controlled studyType 2 diabetesJPRN-UMIN000018440Department of Cardiovascular Medicine, Saga University479